Abstract 170P
Background
The interaction between gastric cancer (GC) tumor cells and tumor microenvironment could impact on the response to conventional chemotherapies (CT). The aim of this study was to obtain a wide transcriptomic profile with spatial resolution of tissue samples from locally advanced GC patients (pts) who present extremely different response to neoadjuvant CT (NCT).
Methods
Nanostring GeoMx Digital Spatial Profiler (DSP) was performed on pre-therapy biopsies and matched surgical specimens from 6 patients who received NCT. Three pts reached a complete pathological response (CRs), the remaining do not respond (NRs). Regions of interest were visualized on FFPE sections based on immunofluorescent staining for nuclear (DNASyto13), tumor (Pan-cytokeratin) and immune cell (CD45) compartments. Expression levels of more 1,800 genes were evaluated by using the Cancer Transcriptome Atlas (CTA) panel. Transcripts counts were generated using NextSeq 550 instrument (Illumina) and analysed by DSP analysis suite (Nanostring). Effector memory T cells were analysed by immunoistochemistry using CD45RO antibody.
Results
Cells in the tumor compartment of CRs presented an enrichment of deregulated pathways involved in extracellular matrix (ECM) organization and degradation, whereas key pathways involved in cell junction organization, interferon signaling and cell-cell communication were upregulated in NRs. Higher levels of intratumoral CD45RO staining was observed in CRs. A high number of pathways, mainly related to the ECM remodelling and cell surface interaction, as for tumoral cells, resulted upregulated in immune compartment of CRs. Conversely, lymphocytes in NRs were characterized by enrichment in genes involved in the signaling by B cell receptor and generation of second messenger molecules.
Conclusions
A comprehensive characterization of the expression profile of tumor and immune cells showed the contribution of both compartments in the chemosensitivity, mainly through the regulation of ECM organization and remodeling. DSP-based analyses will help to decipher the different responses of GC patients to chemotherapy, enabling the identification of potential biomarker signatures.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\".
Funding
Italian Ministry of Health within the ERAPerMed Project GRAMMY (ERP-2019-23671108; GRAMMY, 2019-275).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes
Presenter: Rowan Howell
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
Presenter: Giorgia Bortolus
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Physician perceptions and the evolving landscape of next generation sequencing (NGS) use across EU4+UK
Presenter: Keerun Khela
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)
Presenter: Phoebe Cheng
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Clinical implementation of NGS and ESCAT for optimized cancer therapy
Presenter: AI. Martin-Quesada
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Prevalence of homologous recombination repair deficiency-associated variants in non-selected Portuguese patients with metastatic prostate cancer
Presenter: Tiago Barroso
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany
Presenter: Maike Collienne
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Molecular tumor board for advanced cancer patients offers new therapeutic opportunities beyond level 1 ESCAT scale
Presenter: Victor Segui-Manzaneque
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - NICE recommendations and ESMO-MCBS/ESCAT scores for solid tumour drugs
Presenter: Eunice Xing
Session: Cocktail & Poster Display session
Resources:
Abstract